Advertisement
Screener

Biofrontera Inc. (BFRI) Income (Loss) from Equity Method Investments

2.1 / 5 stars · 19/46 Roast Me

Biofrontera Inc. Income (Loss) from Equity Method Investments

Biofrontera Inc. (BFRI) reported Income (Loss) from Equity Method Investments of -$1.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Income Statement › Other Income

us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-13

  • Biofrontera Inc. income (loss) from equity method investments for the quarter ending 2025-12-31 was -$1.00K.
  • Biofrontera Inc. income (loss) from equity method investments for the quarter ending 2025-09-30 was $1.00K.
  • Biofrontera Inc. income (loss) from equity method investments for the quarter ending 2024-12-31 was -$2.00K.
  • Biofrontera Inc. income (loss) from equity method investments for the quarter ending 2024-09-30 was -$1.00K.
  • Biofrontera Inc. income (loss) from equity method investments for fiscal 2025 was $2.00K.
  • Biofrontera Inc. income (loss) from equity method investments for fiscal 2024 was -$14.00K.
  • Biofrontera Inc. income (loss) from equity method investments for fiscal 2023 was -$7.42M, a 524.79% decline from fiscal 2022.
  • Biofrontera Inc. income (loss) from equity method investments for fiscal 2022 was $1.75M.
Period endIncome (Loss) from Equity Method Investments 3 monthIncome (Loss) from Equity Method Investments 6 monthIncome (Loss) from Equity Method Investments 9 monthIncome (Loss) from Equity Method Investments 12 month
2026-06-30-$1.00K
10-Q · filed 2026-08-13
2025-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
$0.00
derived: sum of 2 quarters · filed 2026-03-19
$2.00K
10-K · filed 2026-03-19
2025-09-30$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$3.00K
10-Q · filed 2025-11-12
2025-06-30$2.00K
10-Q · filed 2026-08-13
2024-12-31-$2.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$3.00K
derived: sum of 2 quarters · filed 2026-03-19
-$17.00K
derived: sum of 3 quarters · filed 2026-03-19
-$14.00K
10-K · filed 2026-03-19
2024-09-30-$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$15.00K
derived: sum of 2 quarters · filed 2025-11-12
-$12.00K
10-Q · filed 2025-11-12
-$798.00K
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$14.00K
10-Q · filed 2024-08-14
-$11.00K
10-Q · filed 2025-08-13
-$797.00K
derived: sum of 3 quarters · filed 2025-05-15
-$3.01M
derived: sum of 4 quarters · filed 2025-05-15
2024-03-31$3.00K
10-Q · filed 2025-05-15
-$783.00K
derived: sum of 2 quarters · filed 2025-05-15
-$3.00M
derived: sum of 3 quarters · filed 2025-05-15
-$4.48M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$786.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$3.00M
derived: sum of 2 quarters · filed 2025-03-20
-$4.48M
derived: sum of 3 quarters · filed 2025-03-20
-$7.42M
10-K · filed 2025-03-20
2023-09-30-$2.21M
10-Q · filed 2023-11-09
-$3.69M
derived: sum of 2 quarters · filed 2024-08-14
-$6.63M
10-Q · filed 2024-11-14
2023-06-30-$1.48M
10-Q · filed 2024-08-14
-$4.42M
10-Q · filed 2024-08-14
2023-03-31-$2.94M
10-Q · filed 2024-05-15
2022-12-31$1.75M
10-K · filed 2024-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Rocket One Inc. (RKTO)United States$0.019B
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Korsana Biosciences, Inc. (CYCN)United States$0.016B